Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL999210 | 0.98 | GAA (0.58) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28551255 | 0.92 | GAA (0.63) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31488724 | 0.79 | KDM4E (0.41) | GAAALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL10466189 | 0.77 | KDM4E (0.43) | GAAALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL15283000 | 0.77 | GAA (0.95) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3630393 | 0.77 | GAA (0.85) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3634814 | 0.77 | GAA (0.85) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL27714921 | 0.76 | KDM4E (0.46) | GAAALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL13902802 | 0.76 | GAA (0.60) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16438889 | 0.76 | SMN1; SMN2 (0.53) | GAAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2023207875-A1 | CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2023-11-02 | — | — | WO | claimed |
| EP-3433249-B1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL SCIENT IND RES (IN) | 2022-11-09 | — | — | EP | claimed |
| CN-109651297-B | N-benzyl-N-aryl sulfonamide derivative and preparation and application thereof | 杭州壹瑞医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-110023315-B | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2021-11-12 | — | — | CN | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| CN-113226469-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-108135175-B | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-109705033-B | N-heteroaryl sulfonamide derivative, preparation and application | 杭州壹瑞医药科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-111801099-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2020-10-20 | — | — | CN | claimed |
| CN-103261202-B | As the fused tricyclic compounds of adenosine receptor antagonists | ADVINUS THERAPEUTICS LTD. (IN) | 2016-01-20 | — | — | CN | claimed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | claimed |
| EP-2861603-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE - 5 - (6H) - ONE COMPOUNDS | Dart NeuroScience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | claimed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013192229-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE - 5 - (6H) - ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | claimed |
| CN-103261202-A | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LTD | 2013-08-21 | — | — | CN | claimed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | claimed |
| CN-102448958-A | Pyrimidinyl and 1,3, 5-triazinyl benzimidazole sulfonamides and their use in the treatment of cancer | PATHWAY THERAPEUTICS LTD | 2012-05-09 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | MAPT, PYGB, PSEN2 | GAA 1408/4885ALDH1A1 303/4885KDM4E 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.